Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.

Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Singhal S, Smith C, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2015 Nov;13(11):1398-435.

2.

Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma.

Zhou M, Zhao H, Wang Z, Cheng L, Yang L, Shi H, Yang H, Sun J.

J Exp Clin Cancer Res. 2015 Sep 11;34:102. doi: 10.1186/s13046-015-0219-5.

3.

Amplification of 1q21 and other abnormalities in multiple myeloma patients from a tertiary hospital in singapore.

Lim AS, Krishnan S, Lim TH, See K, Ng YJ, Tan YM, Choo N, Lau LC, Tien SL, Ma J, Tan D.

Indian J Hematol Blood Transfus. 2014 Dec;30(4):253-8. doi: 10.1007/s12288-013-0294-8. Epub 2013 Sep 4.

4.

Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myeloma.

Isoda A, Kaira K, Iwashina M, Oriuchi N, Tominaga H, Nagamori S, Kanai Y, Oyama T, Asao T, Matsumoto M, Sawamura M.

Cancer Sci. 2014 Nov;105(11):1496-502. doi: 10.1111/cas.12529. Epub 2014 Oct 9.

5.

Hematopoietic progenitor cell collection after autologous transplant for multiple myeloma: low platelet count predicts for poor collection and sole use of resulting graft enhances risk of myelodysplasia.

Papanikolaou X, Rosenbaum ER, Tyler LN, Sawyer J, Heuck CJ, Barlogie B, Cottler-Fox M.

Leukemia. 2014 Apr;28(4):888-93. doi: 10.1038/leu.2013.214. Epub 2013 Jul 15.

6.

The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma.

Johnson SK, Heuck CJ, Albino AP, Qu P, Zhang Q, Barlogie B, Shaughnessy JD Jr.

Int J Hematol. 2011 Oct;94(4):321-33. doi: 10.1007/s12185-011-0948-y. Epub 2011 Oct 15. Review.

7.

Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis.

Balakumaran A, Robey PG, Fedarko N, Landgren O.

Expert Rev Mol Diagn. 2010 May;10(4):465-80. doi: 10.1586/erm.10.31. Review.

8.

Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma.

Chng WJ, Gertz MA, Chung TH, Van Wier S, Keats JJ, Baker A, Bergsagel PL, Carpten J, Fonseca R.

Leukemia. 2010 Apr;24(4):833-42. doi: 10.1038/leu.2010.21. Epub 2010 Mar 11.

9.

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.

Nair B, van Rhee F, Shaughnessy JD Jr, Anaissie E, Szymonifka J, Hoering A, Alsayed Y, Waheed S, Crowley J, Barlogie B.

Blood. 2010 May 27;115(21):4168-73. doi: 10.1182/blood-2009-11-255620. Epub 2010 Feb 2.

10.

The molecular characterization and clinical management of multiple myeloma in the post-genome era.

Zhou Y, Barlogie B, Shaughnessy JD Jr.

Leukemia. 2009 Nov;23(11):1941-56. doi: 10.1038/leu.2009.160. Epub 2009 Aug 6. Review.

11.

Neurobeachin (NBEA) is a target of recurrent interstitial deletions at 13q13 in patients with MGUS and multiple myeloma.

O'Neal J, Gao F, Hassan A, Monahan R, Barrios S, Kilimann MW, Lee I, Chng WJ, Vij R, Tomasson MH.

Exp Hematol. 2009 Feb;37(2):234-44. doi: 10.1016/j.exphem.2008.10.014. Erratum in: Exp Hematol. 2009 Apr;37(4):532. Kilimann, Manfred W [added].

12.

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.

Barlogie B, Pineda-Roman M, van Rhee F, Haessler J, Anaissie E, Hollmig K, Alsayed Y, Waheed S, Petty N, Epstein J, Shaughnessy JD Jr, Tricot G, Zangari M, Zeldis J, Barer S, Crowley J.

Blood. 2008 Oct 15;112(8):3115-21. doi: 10.1182/blood-2008-03-145235. Epub 2008 May 20.

13.

An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma.

Xiong W, Wu X, Starnes S, Johnson SK, Haessler J, Wang S, Chen L, Barlogie B, Shaughnessy JD Jr, Zhan F.

Blood. 2008 Nov 15;112(10):4235-46. doi: 10.1182/blood-2007-10-119123. Epub 2008 Mar 12.

14.

Suppression of abnormal karyotype predicts superior survival in multiple myeloma.

Arzoumanian V, Hoering A, Sawyer J, van Rhee F, Bailey C, Gurley J, Shaughnessy JD Jr, Anaissie E, Crowley J, Barlogie B.

Leukemia. 2008 Apr;22(4):850-5. doi: 10.1038/sj.leu.2405091. Epub 2008 Jan 17.

15.

CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms.

Zhan F, Colla S, Wu X, Chen B, Stewart JP, Kuehl WM, Barlogie B, Shaughnessy JD Jr.

Blood. 2007 Jun 1;109(11):4995-5001. Epub 2007 Feb 15.

16.

Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.

Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Zangari M, Dhodapkar M, Shaughnessy JD Jr.

Blood. 2007 Feb 15;109(4):1692-700. Epub 2006 Oct 5.

17.

The molecular classification of multiple myeloma.

Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD Jr.

Blood. 2006 Sep 15;108(6):2020-8. Epub 2006 May 25.

18.

Microarray-based understanding of normal and malignant plasma cells.

De Vos J, Hose D, Rème T, Tarte K, Moreaux J, Mahtouk K, Jourdan M, Goldschmidt H, Rossi JF, Cremer FW, Klein B.

Immunol Rev. 2006 Apr;210:86-104. Review.

19.

The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature.

Moreaux J, Cremer FW, Reme T, Raab M, Mahtouk K, Kaukel P, Pantesco V, De Vos J, Jourdan E, Jauch A, Legouffe E, Moos M, Fiol G, Goldschmidt H, Rossi JF, Hose D, Klein B.

Blood. 2005 Aug 1;106(3):1021-30. Epub 2005 Apr 12.

20.

NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.

van Rhee F, Szmania SM, Zhan F, Gupta SK, Pomtree M, Lin P, Batchu RB, Moreno A, Spagnoli G, Shaughnessy J, Tricot G.

Blood. 2005 May 15;105(10):3939-44. Epub 2005 Jan 25.

Supplemental Content

Support Center